Gene Synthesis Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Global Gene Synthesis Market Trends and Insights

Surging Genomics & NGS-Driven R&D Pipelines

More than 900 active clinical trials in North America now incorporate synthetic DNA constructs, underscoring how next-generation sequencing pushes laboratories toward higher-throughput build capabilities. CEPI has committed USD 4.7 million to automate DNA Script’s template production so vaccine developers can move from design to bench in days rather than weeks ^{[2]CEPI, “Funding Award to DNA Script,” cepi.net} . Academic progress supports the driver: University of Hawaii researchers achieved 96% editing success when using high-fidelity templates, demonstrating direct links between synthesis quality and therapeutic efficacy ^{[3]University of Hawaii, “High-Fidelity Gene Editing Study,” hawaii.edu}. NHGRI’s USD 2.2 million grant for multiplex oligo synthesis further embeds synthetic DNA as critical research infrastructure. Together, these elements enlarge sample backlogs and create premium opportunities for providers able to guarantee error-free sequences on demand.  

Expanding Biopharma Demand for Synthetic Genes

Biopharmaceutical pipelines now depend on custom genes for cell therapies, mRNA vaccines, and antibody-drug conjugates. The FDA cleared five gene therapies in 2024, including the first CRISPR-edited treatment, and each approval validates commercial need for precise, viral-vector-ready inserts. GSK invested USD 35 million in Elegen to secure linear DNA that fits its mRNA vaccine portfolio. Clinically, Casgevy prevented severe vaso-occlusive crises in 93.5% of treated sickle-cell patients, proving that accurate template design translates into therapeutic success. Investor sentiment mirrors demand; Constructive Bio attracted USD 58 million in Series A funding as synthetic genomics promises to ease global peptide shortages. These developments shorten development timelines and intensify competition for trustworthy synthesis partners.

Government Genomics-Funding Initiatives

The NHGRI has allocated USD 1.5 million annually through 2029 to accelerate platform technologies, including enzymatic oligo production. India’s BioE3 framework backs precision biotherapeutics and biomanufacturing with fiscal incentives and regulatory streamlining. The European Union’s SYNBEE project offers grants that help startups integrate AI with DNA design. Japan targets a biotechnology market worth 15 trillion yen by 2030 and emphasizes induced pluripotent stem-cell research that relies on long synthetic genes. Public funding reduces commercial risk, expands installed synthesis capacity, and lifts regional adoption rates.  

Rapid Drop in DNA-Synthesis Cost & Turnaround

Enzymatic platforms now allow same-day oligo printing without hazardous solvents, narrowing the gap between sequencing and synthesis speeds. Ribbon Biolabs recently demonstrated 20 kb fragments featuring 0.33% error rates, which expands addressable gene length beyond what chemical methods routinely manage. The University of California Irvine’s proof-of-concept 10-92 TNA polymerase shows academia’s role in boosting both yield and fidelity. WuXi STA has scaled to 27 oligonucleotide lines, underscoring global moves to industrial volumes. Cost declines encourage wider experimentation, sustaining double-digit growth for the gene synthesis market.

Scarcity of Skilled Synthetic-Biology Workforce

Synthetic biology blends molecular biology, engineering, and computation, yet most academic curricula still emphasize traditional wet-lab skills. NHGRI earmarked USD 5.25 million to boost workforce diversity, signalling institutional recognition of the shortage. European biotechnology contributes EUR 31 billion to GDP but already suffers talent bottlenecks that curtail start-up scaling. Japan’s venture funding remains low relative to the United States, partly because of limited entrepreneurial depth. Continuous retraining is essential because enzymatic platforms require new skill sets compared with phosphorus-based chemistry. Without enough qualified staff, production lines risk under-utilization, slowing revenue accrual for the gene synthesis market.  

High Capital Cost for Large-Scale Synthesis Capacity

Solid-phase synthesis equipment, purification columns, and waste-handling systems demand multimillion-dollar investments before a single order ships. Molecular Assemblies raised USD 25.8 million solely to commercialize fully enzymatic flow-platforms. Thermo Fisher committed USD 2 billion to expand United States manufacturing and R&D through 2028, revealing the size of budgets required to stay competitive. FDA’s Advanced Manufacturing Technologies program provides regulatory support yet still requires extensive validation, adding expense and time. Smaller entrants that cannot amortize equipment quickly may exit or become acquisition targets, tempering fresh innovation within the gene synthesis market.  

Segment Analysis

By Synthesis Method: Enzymatic Platforms Challenge Chemical Dominance

Chemical oligonucleotide synthesis retained 55.45% gene synthesis market share in 2024 thanks to decades of process optimization and reliable supply chains. Solid-phase phosphoramidite reactions remain standard for short strands, and microchip-based approaches improve batch throughput. Yet the gene synthesis market is pivoting as assembly technologies post a 17.21% CAGR through 2030, propelled by the need for longer constructs in CRISPR and viral vectors.  

Enzymatic platforms such as DNA Script’s SYNTAX produce up to 96 oligos within hours, offering laboratories instant access without toxic solvents. Molecular Assemblies’ fully enzymatic flow technology further reduces error rates while extending read length, positioning it to steal share from incumbent methods. Hybrid strategies that combine chemical speed for short primers with enzymatic assembly for long genes are emerging, ensuring the gene synthesis market continues to diversify rather than converge on a single technique.  

Note: Segment shares of all individual segments available upon report purchase

By Service Type: Viral Gene Synthesis Accelerates Vaccine Development

Antibody DNA synthesis contributed 48.28% of the gene synthesis market size in 2024 because of rising antibody-drug conjugate pipelines and CAR-T cell interest. Viral gene synthesis is set for a 17.34% CAGR as mRNA platforms and viral vectors dominate vaccine and gene-therapy arenas.  

CEPI funding of automated template production confirmed strategic urgency to shorten vaccine R&D cycles. Johnson & Johnson’s collaboration with GenScript on approved CAR-T therapies exemplifies how proprietary antibody sequences generate recurring orders. Service providers capable of bundling sequence design, enzymatic synthesis, and AI-based optimization stand to capture premium contracts, expanding overall revenue for the gene synthesis market.

By Application: Diagnosis Adoption Broadens Commercial Base

Gene and cell therapy represented 52.21% of demand in 2024, strengthened by the FDA’s accelerating approval cadence for one-time genetic treatments. Disease-diagnosis applications will expand at a 17.37% CAGR as hospitals embed genomic assays into routine care.  

Rapid neonatal genome sequencing now proves clinically necessary in 60% of level IV NICU cases, creating daily demand for custom probes and controls. AI-designed regulatory sequences developed by the Centre for Genomic Regulation enable ultra-selective expression, opening new markets for design-plus-build services. Together, these forces sustain diversity in application mix, keeping the gene synthesis market resilient to therapeutic-pipeline volatility. 

Note: Segment shares of all individual segments available upon report purchase

By End User: Outsourcing Propels CRO and CDMO Growth

Biopharmaceutical firms still drove 46.23% of revenue in 2024 by ordering large volumes for internal programs. However, CROs and CDMOs are forecast to record the swiftest 17.43% CAGR as sponsors externalize synthesis to focus on clinical strategy.  

GenScript’s USD 224 million raise earmarked for CDMO expansion signals supplier confidence in the outsourcing wave. Twist Bioscience posted USD 92.8 million revenue for Q2 2025 on the back of diversified customer pools in both synthetic biology and next-generation sequencing. Academic consortia funded by NHGRI further diversify revenue streams, ensuring broad demand stability for the gene synthesis market.  

Geography Analysis

North America commanded 42.31% of the gene synthesis market size in 2024 because of strong venture capital flows, mature biopharmaceutical clusters, and supportive regulation. The NHGRI’s USD 1.5 million annual commitment to platform technologies fosters public-private partnerships, while the FDA’s coordinated gene-therapy review pathway removes regulatory uncertainty. Private firms mirror policy confidence; Thermo Fisher is spending USD 2 billion on domestic capacity expansions through 2028.  

Asia-Pacific is projected to log a 17.61% CAGR through 2030 and is the fastest-growing region in the gene synthesis market. China classifies biotechnology as a strategic pillar and channels generous subsidies into synthetic genetics ventures. India’s BioE3 policy prioritizes precision biotherapeutics and positions local biofoundries to serve global clients. Japan plans to double private drug-discovery investment by 2028, with induced pluripotent stem-cell projects demanding long synthetic sequences. South Korea’s cell-therapy initiatives further reinforce regional momentum.  

Europe remains a steady growth contributor as coordinated policy frameworks such as the EU Bioeconomy Strategy back industrial biotechnology. SYNBEE grants help startups combine AI and DNA design, while the continent’s pharmaceutical giants deliver consistent order volumes. Middle East and Africa along with South America are early in adoption cycles, yet rising healthcare spending and agricultural biotech needs are widening the addressable base for the gene synthesis market.